BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory ...

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

A growing body of evidence is shifting expert opinion toward supporting MS treatment during pregnancy, emphasizing ...

Historically, optic nerve involvement has been excluded from MS diagnostic criteria, but its inclusion in the new iteration ...

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of ...

This was the stock's third consecutive day of losses.

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

In a report released today, Laura Chico from Wedbush maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $121.00. The company’s shares closed y ...

Biogen has highlighted the growing role of felzartamab in its pipeline during a virtual investor seminar, spotlighting three ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $175.00. The company’s shares closed today at $133.06.